Organoid Science Doubles Market Cap in Six Days as 'FDA Animal Testing Abolition' Boosts Demand

Entered KOSDAQ at 21,000 Won per Share on May 9
Next-Generation Regenerative Therapy Developer Using Organoid Technology
Recreating Micro Human Environments with Patient-Derived Organoids

The corporate value of Organoid Science, a next-generation regenerative therapy developer, is rapidly increasing. Recently, the U.S. Food and Drug Administration (FDA) decided to gradually abolish animal testing requirements for monoclonal antibodies and other drugs, which is expected to boost demand for laboratory-grown human organ models (organoids).

According to the financial investment industry on May 19, Organoid Science's stock price rose by 116.9% compared to its initial public offering price of 21,000 won in just six trading days after listing. Its market capitalization has grown to 296 billion won. Since entering the KOSDAQ market on May 9, individual investors have purchased 32.7 billion won worth of shares. The average purchase price was 34,619 won, and based on the current share price of 45,550 won, the evaluation return rate is 31.6%.

Founded in 2018, the company is developing treatments for intractable diseases using 'organoid' technology, which recreates human organs by culturing stem cells in three dimensions. Organoids demonstrate outstanding regenerative capabilities when transplanted into damaged tissues. In addition to developing the regenerative therapy 'ATORM,' the company also provides a new material efficacy evaluation solution called 'ODISEI.'

It is difficult to accurately evaluate rapidly advancing new materials using only traditional animal testing. ODISEI is a solution that increases the efficiency of new drug development by evaluating advanced pharmaceuticals and new materials without animal testing. By implementing tumor microenvironments using patient-derived organoids, it is possible to assess the efficacy of immuno-oncology drugs. Based on disease model creation technology, the company can also clarify the efficacy and mechanisms of disease treatments that are difficult to accurately evaluate with conventional testing methods.

Organoid Science will present its research achievements and future potential for precision medicine and personalized therapies utilizing organoids at the 'ODC 25' organoid conference, which will be held over two days from June 13 to 14.

Park Jongseon, a researcher at Eugene Investment & Securities, explained, "As the movement to abolish mandatory animal testing spreads globally, Organoid Science is applying its new material evaluation solution to a variety of fields, including regenerative therapy, new drug development, precision medicine, companion diagnostics, and cosmetics."

He also expressed expectations that the company would show concrete results in the field of regenerative therapy development. The regenerative therapy market is expected to experience explosive growth. According to the global market research firm Fortune Business Insights, the global regenerative therapy market is projected to grow from 42 billion dollars last year to 398 billion dollars by 2032, with an average annual growth rate of approximately 32.4%.

Organoid Science plans to enter Phase 1 clinical trials in the United States and Europe next year and complete Phase 2 by the end of 2028. The company has been in discussions with multiple multinational pharmaceutical companies regarding regenerative therapy development for the past three years. It announced short-term results of its advanced regenerative bio law clinical research at the 'United European Gastroenterology Week' held in Spain. For the first time in the world, an organoid-based therapy has demonstrated clinical efficacy and safety in intractable intestinal diseases.